STATEMENT: Critical Path Institute appoints Dr. Klaus Romero as new CEO

(Information sent by the signatory company)

-Critical Path Institute appoints Dr. Klaus Romero as new CEO and promotes Cécile Ollivier to vice president of global affairs

AMSTERDAM, Jan. 25, 2024 /PRNewswire/ — Critical Path Institute (C-Path) has named Klaus Romero, M.D., M.S., FCP, as its new CEO and promoted Cécile Ollivier, M.S., to Managing Director for Europe to vice president of global affairs.

With an impressive career spanning more than 16 years at C-Path, Romero has held key positions within the organization, including Chief Scientific Officer and Executive Director of both Clinical Pharmacology and the Quantitative Medicine Program. His pivotal role in establishing and leading the Quantitative Medicine Program underscores his important contributions to C-Path’s critical drug development initiatives over the years.

M. Wainwright Fishburn, Jr., Chairman of the C-Path Board of Directors, commented on the appointment: “Dr. Romero’s outstanding experience and leadership have been instrumental in our journey to create and implement innovative scientific and regulatory pathways. His “This strategic vision aligns perfectly with C-Path’s mission to accelerate the development of novel therapies. We are confident in his ability to propel the organization into its next phase of global impact and pioneering innovation.”

“Taking on the role of CEO of C-Path represents a profound honor, coupled with a tremendous sense of responsibility,” said Romero. “My commitment is to continue C-Path’s tradition of excellence and innovation to transform drug development for the benefit of those in need. This is a commitment deeply rooted in my early days at C-Path, inspired by mentorship and visionary guidance from C-Path founder Dr. Raymond Woosley. Our collaborative efforts will continue to transform drug development paradigms, benefiting those in need.”

For additional information on Dr. Romero’s appointment, please see this link.

Cécile Ollivier has been a key figure at C-Path since joining as CEO in April 2021. In her new role, she will oversee global strategic initiatives, focusing on enhancing international collaborations and developing innovative approaches to address complex challenges in the drug development.

“We are delighted to announce the promotion of Cécile Ollivier to Vice President of Global Affairs,” said Tomas Salmonson Ph.D., M.S., C-Path Board Member. “Cécile has been an invaluable addition to our European operations and her extensive experience in global drug development and regulatory science make her the ideal choice for this expanded role. Her leadership will be crucial as we continue our mission to accelerate drug development worldwide.

With more than 16 years of experience in the healthcare sector, Ollivier has made significant contributions to the development of pediatric and rare disease drugs. Her efforts have been recognized internationally, including as an expert at the International Conference on Harmonization (ICH) and leading the global strategy for pediatric extrapolation. Prior to joining C-Path, Ollivier brought her experience to the European Medicines Agency (EMA) and the medical technology sector, focusing on the development of digital endpoints in clinical trials.

“I am honored to take on this new role,” said Ollivier. “The opportunity to further influence global health outcomes and drive innovation in drug development is a great fit for my passion and experience. I look forward to working with our talented team and partners around the world to make a significant impact that benefits the lives of individuals and families affected by diseases with unmet needs.”

For more information on Ollivier’s appointment, visit this link.

About Critical Path Institute

Critical Path Institute (C-Path) is an independent, nonprofit organization established in 2005 as a public-private partnership in response to the FDA’s Critical Path Initiative. C-Path’s mission is to lead collaborations that advance better treatments for people around the world. Recognized worldwide as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotechnology companies. With dedicated team members located around the world, C-Path’s global headquarters is located in Tucson, Arizona and C-Path’s European affiliate is headquartered in Amsterdam, Netherlands. For more information visit


Roxan Triolo

Photo –…Photo –…Logo – 1180189…

View original content: